Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Tysabri (natalizumab) is a prescription drug that’s used to manage Crohn’s disease and certain kinds of multiple sclerosis (MS). The drug comes as an intravenous (IV) infusion. It’s usually given ...

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...

The back story: Elan and Biogen have a joint agreement over multiple sclerosis drug Tysabri, a likely $1 billion blockbuster. Elan did a $1 billion financing deal with Johnson & Johnson that gives J&J ...

Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...

Today, (NASDAQ: BIIB) and , plc (NYSE: ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28 ...

Everclear frontman Art Alexakis opens up about living with living with multiple sclerosis for more than a decade, the early signs he missed, and why he considers his diagnosis a "blessing.' ...

Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug’s label that could boost sales by helping doctors avoid a serious adverse ...

We are issuing this alert because Elan jumped 24.5% in about 30 minutes of trading Wednesday to close at $15.81 when trading resumed on the New York Stock Exchange after the U.S. Food and Drug ...

Biogen Idec will purchase all rights to the blockbuster multiple sclerosis drug Tysabri from its partner, Elan Pharmaceuticals, for $3.25 billion, adding a capstone to a long and tangled journey for a ...

The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly active multiple sclerosis (MS), a move that expands the drug’s use in ...